Xenetic begins Phase II of XBIO-101 in endometrial cancer

Xenetic Biosciences Inc. (NASDAQ:XBIO) began an open-label, U.S. Phase II trial to evaluate XBIO-101 (sodium cridanimod) plus progestin therapy in about 72 patients with recurrent or persistent endometrial cancer not amenable to surgical treatment or radiotherapy who have either failed progestin monotherapy or are negative for progesterone receptor (PGR).

The trial’s primary endpoint is overall disease control rate (DCR). Secondary endpoints include objective response rate (ORR), progression-free survival (PFS), duration of stable disease and overall survival (OS)...